Aberdeen Group reports 8.94% stake in Quoin ADSs

Quoin Pharmaceuticals, Ltd. received a major shareholder disclosure showing that Aberdeen Group plc and its affiliate abrdn Inc. beneficially own 75,000 American Depositary Shares, representing 8.94% of this class.

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. received a major shareholder disclosure showing that Aberdeen Group plc and its affiliate abrdn Inc. beneficially own 75,000 American Depositary Shares, representing 8.94% of this class. These ADSs each represent thirty-five ordinary shares.

The filing states that Aberdeen Group plc and abrdn Inc. share both voting and dispositive power over all 75,000 ADSs, with no sole authority reported. The holders certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Quoin Pharmaceuticals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Quoin Pharmaceuticals (QNRX) does Aberdeen Group report owning?

Aberdeen Group plc and abrdn Inc. report beneficial ownership of 8.94% of Quoin Pharmaceuticals’ American Depositary Shares. This stake, disclosed in a Schedule 13G filing, reflects a significant institutional holding in the ADS class, each ADS representing thirty-five ordinary shares.

How many Quoin Pharmaceuticals (QNRX) ADSs are beneficially owned by abrdn Inc.?

abrdn Inc. reports beneficial ownership of 75,000 Quoin Pharmaceuticals American Depositary Shares. The filing states abrdn Inc. has shared voting and shared dispositive power over all 75,000 ADSs, held on behalf of underlying clients as part of its asset management activities.

Do Aberdeen Group and abrdn Inc. control voting for their Quoin Pharmaceuticals (QNRX) shares?

Aberdeen Group plc and abrdn Inc. report shared voting power over 75,000 ADSs and no sole voting power. They also report shared dispositive power over the same shares, indicating decisions are made jointly within the group rather than by a single entity alone.

Are Aberdeen Group’s Quoin Pharmaceuticals (QNRX) shares held to influence control of the company?

The filing certifies the Quoin Pharmaceuticals ADSs were acquired and held in the ordinary course of business. It specifically states they were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Which entities in the abrdn group are involved in the Quoin Pharmaceuticals (QNRX) holding?

The disclosure identifies Aberdeen Group plc as the parent company, abrdn Holdings Limited as the intermediate holding company, and abrdn Inc. as the entity that beneficially owns 5% or more of the outstanding ADSs on behalf of underlying clients.

What type of security in Quoin Pharmaceuticals (QNRX) is reported in this ownership filing?

The filing covers American Depositary Shares of Quoin Pharmaceuticals, with each ADS representing thirty-five ordinary shares with no par value. The reported 75,000 ADSs therefore correspond to a significantly larger number of underlying ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 11:05 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quoin Pharmaceuticals, Ltd.

(Name of Issuer)

American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 75,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 75,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

75,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.94 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 75,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 75,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

75,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.94 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals, Ltd.
(b)	Address of issuer's principal executive offices: 23 HATA'AS STREET, KFAR SABA, ISRAEL 44425
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200, Philadelphia, PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share
(e)	CUSIP No.: 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 75,000
(b)	Percent of class: 8.94 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 75,000 abrdn Inc. - 75,000
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 75,000 abrdn Inc. - 75,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	J. Clarke
Name/Title:	Jenny Clarke/Major Shareholding Reporting Analyst
Date:	01/20/2026

abrdn Inc.

Signature:	J. Clarke
Name/Title:	Jenny Clarke/Major Shareholding Reporting Analyst
Date:	01/20/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.